Jan. 12 at 12:34 AM
Attached is our updated tracker of what's happened to the share prices of all 170 new commercial-stage non-oncology focused bios since receiving FDA approval, going back to 1/1/13.
Since we last published,
$DVAX announced it was being acquired. As of Friday's close, DVAX's share price is off 13% since receiving FDA approval.
$FOLD announced it was being acquired for
$14.50 per share, reflecting roughly a 3% increase since its closing share price as of Galafold's 1st approval.
Unlike oncology, there are a few non-oncology focused bios that have gone on to deliver meaningful gains to shareholders post FDA approval.
$VCEL $INSM &
$LQDA share prices are up 800 to 1,000% since their 1st products were approved.
Otherwise, the evidence is overwhelming shareholder value is maximized via sale within 3 years of FDA approval (versus 2 years in oncology) just under 90% of the time.
As always, we may have missed a stock split (especially in those trading lower).
This is not investment advice.
